Compare Stocks: ENTX, AGIO, ADMA, and MESO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.51 +4.4%	$9.21	$7.21 ▼ $20.46	$2.13B	0.78	4.29 million shs	2.86 million shs
AGIO Agios Pharmaceuticals	$33.95 +2.7%	$34.41	$22.24 ▼ $46.00	$2.03B	0.6	1.04 million shs	884,549 shs
ENTX Entera Bio	$2.96	$2.79	$0.91 ▼ $4.20	$514.54M	1.38	1.04 million shs	294,683 shs
MESO Mesoblast	$15.48 +2.3%	$16.18	$13.05 ▼ $21.50	$2.01B	2.12	226,100 shs	165,742 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	-1.30%	-7.42%	+6.30%	-42.74%
AGIO Agios Pharmaceuticals	0.00%	-1.58%	-0.06%	-5.78%	-12.28%
ENTX Entera Bio	0.00%	+4.23%	-8.36%	+100.00%	+64.44%
MESO Mesoblast	0.00%	-2.26%	-11.00%	-2.39%	-11.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.51 +4.4%	$9.21	$7.21 ▼ $20.46	$2.13B	0.78	4.29 million shs	2.86 million shs
AGIO Agios Pharmaceuticals	$33.95 +2.7%	$34.41	$22.24 ▼ $46.00	$2.03B	0.6	1.04 million shs	884,549 shs
ENTX Entera Bio	$2.96	$2.79	$0.91 ▼ $4.20	$514.54M	1.38	1.04 million shs	294,683 shs
MESO Mesoblast	$15.48 +2.3%	$16.18	$13.05 ▼ $21.50	$2.01B	2.12	226,100 shs	165,742 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	-1.30%	-7.42%	+6.30%	-42.74%
AGIO Agios Pharmaceuticals	0.00%	-1.58%	-0.06%	-5.78%	-12.28%
ENTX Entera Bio	0.00%	+4.23%	-8.36%	+100.00%	+64.44%
MESO Mesoblast	0.00%	-2.26%	-11.00%	-2.39%	-11.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	2.50	Moderate Buy	$18.67	96.28% Upside
AGIO Agios Pharmaceuticals	2.55	Moderate Buy	$41.75	22.97% Upside
ENTX Entera Bio	2.33	Hold	$9.00	204.05% Upside
MESO Mesoblast	2.00	Hold	$39.00	151.94% Upside

Current Analyst Ratings Breakdown

Latest ENTX, AGIO, ADMA, and MESO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$46.00 ➝ $50.00
9/18/2026	ENTX Entera Bio	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$9.00
9/18/2026	ENTX Entera Bio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
9/14/2026	ADMA ADMA Biologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
9/2/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/27/2026	MESO Mesoblast	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$35.00 ➝ $39.00
8/24/2026	AGIO Agios Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/7/2026	AGIO Agios Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$31.00 ➝ $34.00
8/4/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/31/2026	AGIO Agios Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$46.00 ➝ $52.00
7/31/2026	AGIO Agios Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$41.00 ➝ $39.00

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$510.17M	4.18	$0.68 per share	13.93	$2.01 per share	4.73
AGIO Agios Pharmaceuticals	$54.03M	37.51	N/A	N/A	$20.46 per share	1.66
ENTX Entera Bio	$40K	12,863.42	N/A	N/A	$0.29 per share	10.21
MESO Mesoblast	$120.25M	16.72	N/A	N/A	$4.38 per share	3.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$146.93M	$0.70	13.59	11.19	N/A	32.98%	40.17%	26.97%	11/4/2026 (Estimated)
AGIO Agios Pharmaceuticals	-$412.78M	-$7.01	N/A	N/A	N/A	-418.24%	-35.67%	-33.06%	10/29/2026 (Estimated)
ENTX Entera Bio	-$11.44M	-$0.35	N/A	N/A	N/A	N/A	-147.19%	-103.22%	11/13/2026 (Estimated)
MESO Mesoblast	-$57.50M	-$0.28	N/A	43.00	N/A	N/A	N/A	N/A	N/A

Latest ENTX, AGIO, ADMA, and MESO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q2 2026	ENTX Entera Bio	-$0.08	-$0.14	-$0.06	-$0.14	N/A	N/A
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million
7/31/2026	Q4 2026	MESO Mesoblast	N/A	-$0.0660	N/A	-$0.0660	N/A	$34.45 million
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.49	6.97	3.81
AGIO Agios Pharmaceuticals	N/A	10.22	9.79
ENTX Entera Bio	N/A	8.98	8.98
MESO Mesoblast	0.19	2.43	2.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
AGIO Agios Pharmaceuticals	N/A
ENTX Entera Bio	14.11%
MESO Mesoblast	1.43%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.90%
AGIO Agios Pharmaceuticals	5.40%
ENTX Entera Bio	10.57%
MESO Mesoblast	18.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	647	223.99 million	215.25 million	Optionable
AGIO Agios Pharmaceuticals	540	59.70 million	56.48 million	Optionable
ENTX Entera Bio	21	173.83 million	155.46 million	Optionable
MESO Mesoblast	108	129.88 million	105.46 million	Optionable

ENTX, AGIO, ADMA, and MESO Headlines

Recent News About These Companies

Reviewing Biogen (NASDAQ:BIIB) and Mesoblast (NASDAQ:MESO)

September 20 at 5:58 AM | americanbankingnews.com

How Mesoblast Limited (MESO) Affects Rotational Strategy Timing

September 6, 2026 | news.stocktradersdaily.comN

Mesoblast (NASDAQ:MESO) Share Price Passes Above 50 Day Moving Average - Time to Sell?

September 4, 2026 | marketbeat.com

Bank of America Corp DE Increases Holdings in Mesoblast Limited $MESO

September 4, 2026 | marketbeat.com

Why brokers see 85% upside for this ASX biotech stock

September 4, 2026 | msn.com

Experts tip these $3 billion ASX shares to deliver over 75% returns

September 1, 2026 | msn.com

Mesoblast (NASDAQ:MESO) Shares Gap Up - Here's Why

August 27, 2026 | marketbeat.com

Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript

August 27, 2026 | seekingalpha.com

Mesoblast Reports Substantial Revenue Growth to US$120M

August 26, 2026 | globenewswire.com

Mesoblast H2 Earnings Call Highlights

August 26, 2026 | marketbeat.com

Mesoblast earnings: Strong revenue growth and operational milestones in FY26

August 26, 2026 | msn.com

Mesoblast Files 2026 Form 20-F, Affirms Status as Well-Known Issuer

August 26, 2026 | tipranks.com

Mesoblast to Outline 2026 Results and Pipeline Progress in Investor Webcast

August 24, 2026 | tipranks.com

Mesoblast Issues 875,000 Unquoted Employee Incentive Options

August 24, 2026 | tipranks.com

Mesoblast Increases Director Philip Krause’s Equity-Based Incentives

August 24, 2026 | tipranks.com

Mesoblast shares jump as Phase 3 chronic back pain trial completes patient treatment

August 19, 2026 | msn.com

MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up

August 18, 2026 | zacks.com

Mesoblast Completes Pivotal Phase 3 Patient Treatment for Chronic Low Back Pain

August 18, 2026 | tipranks.com

Mesoblast share price jumps on blockbuster news

August 17, 2026 | fool.com.au

Mesoblast shares are up sharply. Is this biotech still undervalued?

August 17, 2026 | msn.com

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

August 16, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX, AGIO, ADMA, and MESO Company Descriptions

ADMA Biologics NASDAQ:ADMA

$9.51 +0.40 (+4.39%)

As of 04:00 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Agios Pharmaceuticals NASDAQ:AGIO

$33.95 +0.88 (+2.66%)

As of 04:00 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Entera Bio NASDAQ:ENTX

$2.96 0.00 (0.00%)

As of 04:00 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Mesoblast NASDAQ:MESO

$15.48 +0.35 (+2.31%)

As of 04:00 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENTX, AGIO, ADMA, and MESO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENTX, AGIO, ADMA, and MESO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENTX, AGIO, ADMA, and MESO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX, AGIO, ADMA, and MESO Company Descriptions

ADMA Biologics NASDAQ:ADMA

Agios Pharmaceuticals NASDAQ:AGIO

Entera Bio NASDAQ:ENTX

Mesoblast NASDAQ:MESO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENTX, AGIO, ADMA, and MESO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENTX, AGIO, ADMA, and MESO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENTX, AGIO, ADMA, and MESO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX, AGIO, ADMA, and MESO Company Descriptions

ADMA Biologics NASDAQ:ADMA

Agios Pharmaceuticals NASDAQ:AGIO

Entera Bio NASDAQ:ENTX

Mesoblast NASDAQ:MESO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools